Background/aim: Melanoma arises from the uncontrolled multiplication of melanocytes, and poses an escalating global health concern. Despite the importance of early detection and surgical removal for effective treatment, metastatic melanoma poses treatment challenges, with limited options. Among optional therapies, including chemotherapy and immunotherapy, all-trans retinoic acid (ATRA), a natural metabolite of vitamin A, has shown promise in treating melanoma by inducing differentiation, apoptosis, growth arrest, and immune modulation in melanoma cells. However, ATRA treatment alone can lead to resistance and relapse. Furthermore, sphingomyelin (SM) was implicated in the inhibition of cell proliferation, differentiation, and apoptotic cell death during melanoma progression.
Materials And Methods: The combinational anticancer effects of ATRA and SM on an in vitro B16F10 melanoma model were investigated based on cell viability, apoptotic cell death, cell cycle progression, and gene expression levels; whereas the safety properties of the treatments were tested on RAW264.7 macrophages.
Results: The combination of 123 μM of ATRA + 136 μM of SM was the most effective treatment, showing a 50% reduction in cell proliferation, leading to 53.91% apoptotic cell death in 48 h, and G2/M phase-cell cycle arrest in the B16F10 cells. While 123 μM of ATRA alone did not change the caspase 3 and Bax gene expressions, the combinational ATRA + SM treatment resulted in 2- and 5-fold increases in the gene expression level, respectively. A 13-fold increase in cyclin-dependent kinase inhibitor 2A was observed with the combinational ATRA + SM treatment, while suppressing the programmed death ligand 1 (PD-L1) expression by 0.5-fold.
Conclusion: Combinational ATRA and SM therapy could be a promising therapeutic approach for melanoma, potentially improving efficacy, while reducing toxicity to healthy cells.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11698197 | PMC |
http://dx.doi.org/10.55730/1300-0152.2715 | DOI Listing |
Turk J Biol
October 2024
Department of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, İstanbul, Turkiye.
Background/aim: Melanoma arises from the uncontrolled multiplication of melanocytes, and poses an escalating global health concern. Despite the importance of early detection and surgical removal for effective treatment, metastatic melanoma poses treatment challenges, with limited options. Among optional therapies, including chemotherapy and immunotherapy, all-trans retinoic acid (ATRA), a natural metabolite of vitamin A, has shown promise in treating melanoma by inducing differentiation, apoptosis, growth arrest, and immune modulation in melanoma cells.
View Article and Find Full Text PDFPLoS One
December 2024
Department of Clinical Laboratory, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan.
Differentiation therapy with all-trans retinoic acid (ATRA) is well established for acute promyelocytic leukemia (APL). However, the narrow application and tolerance development of ATRA remain to be improved. A number of kinase inhibitors have been reported to induce cell differentiation.
View Article and Find Full Text PDFCurr Issues Mol Biol
November 2024
Department of Anatomy, Faculty of Medicine, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur 56000, Malaysia.
The limited availability of corneal tissue grafts poses significant challenges in the treatment of corneal blindness. Novel treatment utilizes stem cell grafts transplanted from the healthy side of the cornea to the damaged side. However, this procedure is only possible for those who have one-sided corneal blindness.
View Article and Find Full Text PDFPLoS One
December 2024
Department of Hematology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Aims: Acute promyelocytic leukemia (APL) progresses quickly and often leads to early hemorrhagic death. Treatment with all-trans retinoic acid (ATRA) promotes differentiation of APL cells and clinical remission, making APL a potentially curable malignancy. Understanding how ATRA works may lead to new treatments for other types of leukemia.
View Article and Find Full Text PDFPurpose: Ambient light exposure is linked to myopia development in children and affects myopia susceptibility in animal models. Currently, it is unclear which signals mediate the effects of light on myopia. All- retinoic acid (atRA) and dopamine (DA) oppositely influence experimental myopia and may be involved in the retino-scleral signaling cascade underlying myopic eye growth.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!